TET1 is a Tumor Suppressor That Inhibits Papillary Thyroid Carcinoma Cell Migration and Invasion

Shuang Yu, Yali Yin, Shubin Hong, Siting Cao, Yanrui Huang, Shuwei Chen, Yujie Liu, Hongyu Guan, Quan Zhang, Yanbing Li, and Haipeng Xiao

1Department of Endocrinology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China
2Department of Endocrinology, Peking University Shenzhen Hospital, Shenzhen 518036, China
3Department of Head and Neck Surgery, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China
4State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, China
5Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China

Correspondence should be addressed to Haipeng Xiao; xiaohp@mail.sysu.edu.cn

Received 29 July 2019; Revised 9 December 2019; Accepted 18 December 2019; Published 8 February 2020

Academic Editor: Thomas J. Fahey

Copyright © 2020 Shuang Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Ten-eleven translocation (TET) enzymes catalyze the oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) promoting demethylation in cells. However, the expression pattern and biologic significance of TET in papillary thyroid carcinoma (PTC) remain unclear. This study aimed to elucidate the biological functions of TET1 and the miRNA and mRNA expression levels in PTC cell lines with downregulated TET1.

Methods. The expression of the TET family in 49 PTC tissues and corresponding tumor-adjacent tissues, as well as PTC cell lines (BCPAP, K1, and TPC-1) and the normal thyroid epithelial cell line (Nthy-ori 3-1), were detected using quantitative real-time polymerase chain reaction. The 5hmC level was detected in PTC tissues and cell lines using immunohistochemistry and dot blot assay, respectively. After silencing the TET1 gene with siRNAs in BCPAP and TPC-1 cells, cell proliferation was detected using EdU assay. Transwell assay was used to investigate cell migration and invasion. miRNA and mRNA expression arrays were conducted in TET1-depleted BCPAP cells.

Results. The expression level of TET1 decreased in PTC tissues and cell lines and was consistent with the reduction in the 5hmC level. The knockdown of the TET1 gene promoted cell migration and invasion in BCPAP cells. The expression of miR-7, miR-15/16 cluster, and let-7 family was downregulated, while the expression of let-7e was upregulated after siRNA-TET1 treatment in BCPAP cells. The expression of WNT4, FZD4, CDK6, MCF2L, and EDN1 was upregulated as potential target genes of dysregulated miRNAs.

Conclusion. This study showed that TET1 dysfunction inhibited the migration and invasion of BCPAP cells and might have a potential role in the pathogenesis of PTC.

1. Introduction

The incidence of thyroid carcinoma (TC), the most common endocrine malignancy, has increased rapidly worldwide in recent years. Furthermore, the prevalence of papillary thyroid carcinoma (PTC), accounting for more than 90% of TC, has also increased more than threefold worldwide in the last 30 years [1, 2]. Although early PTC has a good prognosis, its 5-year survival rate is only 59% in the advanced stage, and the recurrence rate of total PTC is as high as 35% [3]. Therefore, searching for specific molecular markers and exploring the underlying mechanisms of PTC pathogenesis are of great importance for providing new therapeutic targets and improving the prognosis of patients with PTC.

DNA methylation has an essential role in the remodeling of the chromatin structure during development and tissue differentiation [4, 5]. Aberrant DNA methylation, characterized by genome-wide hypomethylation and regional hypermethylation, is common in various forms of cancers. It is closely associated with tumor initiation and progression [6, 7]. In normal cells, DNA methylation is mediated through the coordinated actions of several DNA
methyltransferases (DNMTs), which transfer a methyl group from S-adenosyl methionine to carbon-5 position of the cytosine residues of CpG dinucleotides [4, 5, 8].

5-Hydroxymethylcytosine (5hmC), an intermediate of DNA demethylation process, is a recently discovered epigenetic modification catalyzed by the ten-eleven translocation (TET) proteins, leading to eventual DNA demethylation [9, 10]. TET family members, including TET1, TET2, and TET3, progressively oxidize 5-methylcytosine (5mC) to 5hmC, 5-formylcytosine, and 5-carboxylyosine. 5hmC was found to be downregulated in hematological malignancies and a variety of solid tumors such as prostate, breast, liver, and stomach tumors [11–14]. The degradation of TET proteins was found in many malignancies, and the functional experiments confirmed that TET family members acted as tumor-suppressor genes for the conversion of 5mC into 5hmC in cancers. TET2 mutations with decreased 5hmC are associated with myeloid cancers [15]. TET1 is downregulated in prostate and breast cancer tissues. It maintains the expression of tissue inhibitors of metalloproteinase family proteins 2 and 3 by inhibiting their DNA methylation [14]. However, to date, the expression patterns of TET family members and 5hmC in PTC remain unknown. This study aimed to elucidate the biological functions of TET1 and explore the possible microRNA (miRNA) and mRNA expression levels with downregulated TET1 in BCPAP cells.

2. Methods

2.1. Clinical Specimens. A total of 49 patients with pathologically confirmed PTC were enrolled at the First Affiliated Hospital of Sun Yat-sen University and Sun Yat-sen University Cancer Center (Guangzhou, China) between December 2014 and December 2016. PTC and adjacent normal tissue samples were obtained and stored at –80°C. FFPE surgical samples previously diagnosed as PTC, and benign thyroid nodules were obtained from the First Affiliated Hospital of Sun Yat-sen University between December 2014 and July 2015. The surgical procedure was performed on all patients, and the final diagnoses were based on the pathological examination. All participants provided informed consent, and the study was approved by the ethics committee of Sun Yat-sen University.

2.2. Cell Culture and Transfection. Human thyroid normal cell line Nthy-ori 3-1 and PTC cell lines BCPAP and TPC-1 were kindly given by Dr. Haixia Guan (The First Affiliated Hospital of China Medical University, Shenyang, China). K1, another PTC cell line, was purchased from the European Collection of Cell Cultures (Salisbury, UK). The cells were maintained at 37°C in Dulbecco’s modified Eagle’s medium (Invitrogen, USA) with 10% fetal bovine serum (FBS). RNA oligoribonucleotides were transfected using Lipofectamine 2000 (Invitrogen, USA) as per manufacturer’s instructions. All siRNA oligoribonucleotides and negative control (NC) were obtained from GenePharma (Shanghai, China). The sequences of siRNAs were as follows: TET1 si-RNA1 sense: 5′-GAAGCGAAGAACCUCUUATT-3′; antisense: 5′-UAAAGGGUUCUUGCGCUUCTT-3′; TET1 si-RNA2 sense: 5′-GCGAAAGGUCAAAUUAAUUTT-3′; antisense: 5′-AUUAUUUGUACCUCUUGC-3′; and NC sense: 5′-UUCUCGAACGUGUAAGCUGTT-3′; antisense: 5′-ACGUGACGUUCGGAGATT-3′.

2.3. RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction Analysis. Total RNA was extracted with TRIzol reagent (Life Technologies, USA) according to the manufacturer’s instructions. The human TET1, TET2, and TET3 cDNAs were reverse-transcribed using a PrimeScript real-time polymerase chain reaction (RT-PCR) kit (TaKaRa, China) and quantified by SYBR Premix Ex Taq (TaKaRa, China) using a Light Cycler 480 system (Roche Diagnostics, Switzerland). GAPDH was used as a reference for the normalization of the expression of mRNAs. The oligonucleotide sequences of primers were as follows: TET1 forward primer: 5′-CCCTTGGAATGCCATAGGA-3′; reverse primer: 5′-AGAGCCCTGCTGAATGTGTT-3′; TET2 forward primer: 5′-TAAGGCAGGATTGCGCCATG-3′; reverse primer: 5′-ACCTGTAGGGTGTGCGCTGTT-3′; TET3 forward primer: 5′-GCAACTTCAA-CATACCTGCCAC-3′; reverse primer: 5′-CACC-TGGATGTGGGACTGTGTAA-3′; and GAPDH forward primer: 5′-GCCAGGTTTGGCAAGTG-3′; reverse primer: 5′-TGGTGAAGACGCCAGTGGA-3′. The relative expression was quantified using the comparative cycle threshold method (2−ΔΔCt).

2.4. Western Blot Assay. The proteins were resolved using 10% SDS-PAGE (BioRad, USA), transferred to PVDF membranes (Millipore, USA), and blotted with the following antibodies overnight at 4°C: anti-TET1 (GTX124207, GenTex, USA), anti-TET2 (ab94580, Abcam, UK), anti-TET3 (GTX124207, GenTex, USA), and anti-GAPDH (#sc-25778, Santa Cruz, USA). The membranes were incubated with peroxidase-conjugated anti-rabbit secondary antibodies (CST, USA). The reactions were detected by enhanced chemiluminescence (Thermo, USA).

2.5. Immunohistochemistry. The paraffin-embedded tissue sections were deparaffinized and hydrated using xylene and graded alcohol to water. Antigen retrieval was performed by incubating the tissue sections with boiled sodium citrate buffer (pH 6.0) for 3 min. The endogenous peroxidase activity was quenched with 3% H2O2. The slides were blocked with 5% BSA to reduce nonspecific binding and then incubated with 5hmC (#39791, Avtive Motif, USA) primary antibody overnight at 4°C. After incubation with the secondary antibody (Gene Tech, USA) for 30 min at room temperature, the slides were detected with the DAB Enhancer solution (GeneTech, USA) and counterstained with hematoxylin. The images were taken by light microscopy.

2.6. Dot Blot Assay. The genomic DNA was extracted with a DNeasy Blood and Tissue kit (Omega, USA) according to the
manufacturer’s instructions. Then, the DNA was broken into fragments of about 500 bp by sonication. A proper amount of broken DNA samples were boiled at 95°C for 10 min and quickly placed into the ice water for DNA denaturation. The denatured DNA (1-2 μL) was dripped on a nitrocellulose membrane. After washing with 2x SSC buffer and ultraviolet crosslinking, the membrane was dried at 70°C for 1-2 h, blocked, incubated, and subjected to Western blot analysis. To ensure the equal spotting of DNA as a control, the same blot was stained in 0.02% methylene blue liquid.

2.7. EdU Assay. EdU assay was performed to assess the cell proliferative ability using the EdU kit (RiboBio, China) following the manufacturer’s instructions.

2.8. Cell Migration and Invasion Assays. The cells resuspended in 100 μL of serum-free medium were plated in the top chamber of each insert (Corning, USA) with a non-Matrigel-coated membrane for the Transwell migration assay and a Matrigel-coated membrane (BD Bioscience, USA) for the invasion assay. The lower chambers of the inserts were filled with 600 μL of the medium with 10% FBS. After several hours of incubation, the cells that invaded to the lower surface of the insert were fixed, stained, and imaged using a DMI4000B inverted microscope (Leica, Germany).

2.9. miRNA Array and mRNA Expression Array. BCPAP cells following siRNA-mediated knockdown of TET1 and control cells were used for gene expression profiling analysis. Total RNA was harvested from the aforementioned cell lines using TRIzol reagent (Invitrogen, USA) and an miRNeasy mini kit (Qiagen, Germany) according to the manufacturer’s instructions. For the miRNA array, total RNA was labeled using a miRCURY Array Power Labeling kit (Exiqon, Denmark) and then hybridized on a miRCURY LNA Array (v.18.0, Exiqon, Denmark) using a hybridization system (Nimblegen Systems, USA). Following several washing steps using a wash buffer kit (Exiqon, Denmark), the slides were scanned using an Axon GenePix 4000B microarray scanner (Axon Instruments, USA). For mRNA expression array, total RNA was transcribed into fluorescent cRNA using a Quick Amp Labeling Kit (Agilent Technologies, USA). The labeled cRNA was then hybridized onto the Human Genome Oligo Microarray (4x44K, Agilent Technologies, USA). After the washing steps, the arrays were scanned using the Agilent Scanner G2505C (Agilent Technologies, USA).

The Agilent Feature Extraction software (version 11.0.1.1, Agilent Technologies, USA) was used to analyze the acquired array images. Quantize normalization and subsequent data processing were performed using the GeneSpring GX v12.1 software package (Agilent Technologies, USA). The differentially expressed mRNAs and miRNAs with statistical significance were identified using volcano plot filtering. The threshold used to screen upregulated or downregulated miRNAs and mRNAs was a fold change of ≥2 and ≥1.5, respectively, and P values of less than 0.05 were considered statistically significant.

2.10. Statistical Analysis. SPSS software (version 21.0) was used for all statistical analyses. The significance of different groups of data was calculated with the two-tailed Students t-test or one-way analysis of variance. All data were presented as the mean ± standard deviation (SD) from at least three replicates. \( P < 0.05 \) was considered statistically significant.

3. Results

3.1. TET Expression in PTC Tissues and Cell Lines. The gene expression of TET1, TET2, and TET3 was examined using qRT-PCR in clinical tissues. The downregulation of TET1 in PTC tissues compared with matched normal thyroid tissues was confirmed (Figure 1(a), \( P < 0.01 \)). Meanwhile, the TET2 gene was significantly lowly expressed in PTC (Figure 1(b), \( P < 0.001 \)). However, the TET3 expression level was not significantly different in PTC and matched normal thyroid tissues (Figure 1(c), \( P = 0.4841 \)). The mRNA expression levels of TET1 and TET3 genes significantly decreased in BCPAP and K1 cells (Figure 1(d)). On the contrary, TET2 was highly expressed in PTC cells compared with Nthy-ori 3-1 cells. The expression levels of TET1 and TET3 proteins in PTC cell lines were found to be decreased using Western blot assay (Figure 1(e)).

The expression level of TET1 significantly reduced in both PTC cell lines and clinical tissues. Also, TET3 expression was downregulated in PTC cell lines but had no difference in PTC tissues. However, TET2 expression was not aligned in cells and tissues: strikingly upregulated in PTC cell lines but decreased in PTC tissues. These observations provided a clue that TET1 was the major factor in PTC.

To explore the correlation between the expression of TET1 and clinicopathological characteristics of patients with PTC, 36 patients were divided into 2 groups \( (n = 16 > \text{mean}; \ n = 33 \leq \text{mean}) \) according to the mean expression level of TET1. As shown in Supplementary Table 1, the TET1 expression level positively correlated with tumor size (\( P = 0.027 \)). The data showed that more invasive and advanced-stage cancers had a lower expression level of TET1. However, no significant \( P \) value was found. This was probably due to the small number of clinical samples.

3.2. 5hmC Expression in PTC Tissues and Cell Lines. PTC tissues and benign thyroid nodule tissues were chosen to assess 5hmC levels using immunohistochemical (IHC) analysis. As shown in Figures 2(a) and 2(b), a significant decrease in 5hmC levels was seen in PTC tissues compared with benign thyroid nodules under the same IHC condition (\( P = 0.001 \)), suggesting that the loss of 5hmC was a hallmark of PTC. Furthermore, considering that 5hmC was a modification of DNA, global 5hmC expression was detected in the normal thyroid cell line and PTC cell lines using dot blot assay. A previous study revealed that 5hmC was highly expressed in neuronal tissues but lowly expressed in endocrine tissues [16]. Compared with other studies on gastric cancer and laryngeal squamous cell carcinoma [17, 18], the present study showed that detecting 5hmC expression with
higher amounts of DNA, such as 200 ng and 400 ng, was more sensitive. The data demonstrated that the 5hmC level decreased in PTC cell lines (BCPAP, TPC-1, and K1) compared with the normal thyroid cell line Nthy-ori 3-1 (Figures 2(c) and 2(d)).

3.3. TET1 Inhibited PTC Cell Invasion and Migration. Furthermore, the TET1 gene was silenced in PTC cells with si-TET1 RNAs, and the biological function of TET1 was explored. BCPAP cells were chosen for the higher background expression of the TET1 gene. The results of qRT-PCR and Western blot assays demonstrated a significant decline in the TET1 level after transfection (Figures 3(a) and 3(b)). Dot blot assay showed a concomitant decrease in the 5hmC level after 48 h of transfection (Figures 3(c) and 3(d)) in BCPAP cells. Thus, the study confirmed the high transfection efficiency of si-RNA1 and si-RNA2 and suggested that TET1 was the main regulator of 5hmC generation in BCPAP cells.

Then, the study examined the potential role of TET1 in cell proliferation in BCPAP and TPC-1 cells. EdU incorporation assay was conducted to examine the potential role of TET1 in cell proliferation after si-TET1 and si-TET2 transfection. A growth-promoting tendency was observed in the si-TET1 group, but the result had no statistical significance in BCPAP (Figures 3(e) and 3(f)) and TPC-1 cells (Supplementary Figures 1(a) and 1(b)).

To determine whether TET1 could influence the migration and invasion ability of BCPAP and TPC-1 cells, transwell assays without and with the Matrigel-coated chamber were performed. Strikingly, si-TET1 and si-TET2 were found to promote cell migration and invasion (Figures 3(g)–3(i)) in BCPAP cells, but discrepancy results in TPC-1 cells (Supplementary Figures 1(c)–1(e)). Collectively, the results indicated different cells may have different biology function, and TET1 downregulation facilitated the migration and invasion in BCPAP cells.

3.4. Chip Results after si-TET1. The data suggested that TET1 likely inhibited the migration and invasion of BCPAP cells. The microarray analysis was conducted to understand the specific mechanism involved in this process. The miRNA and gene expression levels between control (NC group) and
TET1-depleted (si-TET1 RNA group) BCPAP cells were analyzed (Supplementary Tables 2 and 3). The fold change in the differential expression of genes and mRNAs was set to be 1.5 and 2, respectively. Then, the genes and miRNAs with a negative expression trend were picked out. Furthermore, 6 miRNAs were found to be upregulated and 32 downregulated (Figure 4(a)). A gene coexpression network was constructed to predict the miRNA targets. Strings between genes and miRNAs showed the potential regulatory relationship (Supplementary Figure 2).

Surprisingly, the expression levels of classic tumor-suppressor genes miR-7 and miR-15/16 significantly decreased after silencing TET1, while let-7e expression was upregulated. Simultaneously, the expression levels of potential target genes, including WNT4 and FZD4 (parts of the canonical Wnt pathway), significantly increased. The expression of proto-oncogenes CDK6, MCF2L, and EDN1 was also upregulated along with WNT4 and FZD4 (Figure 4(b)).

4. Discussion

The newly discovered TET family members catalyze the conversion of 5mC into 5hmC, greatly promoting DNA epigenetic modification. The expression of 5hmC is generally decreased in human tumors [11–14]. Meanwhile, 5hmC has become an important factor for DNA epigenetic modification with the downregulation of the expression of single or multiple members of the TET family.

This study reported that the expression level of TET1 decreased, and the global 5hmC content reduced in PTC tissues and cell lines. The cancer cells with TET1 knockdown showed lower levels of 5hmC, contributing to aberrant DNA methylation patterns in PTC. TET1 was first identified as one of the MLL fusion partners in leukemias [19]; it showed the highest expression levels in embryonic stem cells and in early embryogenesis [20]. Multiple cell lines of evidence supported the tumor-suppressive function of TET1 proteins in endocrine carcinomas, such as breast cancer and ovarian cancer [21, 22]. The present study also showed a significant
Figure 3: TET1 inhibited the invasion and migration in BCPAP cells. (a, b) TET1 level significantly declined after transfection with si-TET1 RNAs as detected using qRT-PCR and Western blot assays. (c) Dot blot assay showed the expression of 5hmC after 48 h of transfection of si-TET1 RNAs (left). Methylene blue staining of the identical membrane was used as the sample control (right). (d) ImageJ software was used to analyze exposure grayscale and showed that the downregulated TET1 expression level was consistent with the reduction in the 5hmC level. (e) EdU incorporation assay was conducted to examine the potential role of TET1 in cell proliferation after si-TET1 and si-TET2 transfection. Fluorescent images of proliferative cells (red) stained with EdU and nuclei (blue) counterstained with DAPI in BCPAP cells. Magnification, 400x. (f) Quantification of EdU incorporation assay in BCPAP cells. (g) Transwell migration and invasion assays of BCPAP cells after si-TET1 and si-TET2 transfection were performed without and with the Matrigel-coated chamber. Magnification, 200x. (h) Quantification of migrated cells. (i) Diagrams of invasive cells. *P < 0.05, **P < 0.01, and ***P < 0.001.
reduction of TET1 in PTC as other endocrine carcinomas. Good et al. uncovered an intricate network connecting TET1 to the hypomethylation and activation of cancer-specific oncogenic pathways, including PI3K, EGFR, and PDGF, using bioinformatic analyses in both breast and ovarian cancer cell lines [21]. Duan et al. reported that TET1 expression was undetected in six types of ovarian cancer cell lines, and the ectopic expression of TET1 inhibited colony formation, cell migration, and invasion in SKOV3 and OVCAR3 cells [22]. The present study provided evidence that ectopic TET1 exerted potent antitumor effects by inhibiting the migration and invasion in BCPAP cells, but discrepancy results in TPC-1 cells. PTC cell lines originate from dedifferentiated in vivo human thyroid tumors and have different mutational status. As reported, BCPAP cells showed BRAF and TP53 mutations, and TPC-1 cells harbored the RET/PTC1 gene rearrangement [23]. The discrepancies of biological function may due to different mutational status of cancer cells, but further study needs to investigate the role of TET1 in different genetic alterations.

Figure 4: Results of miRNA chip and mRNA expression profiles after si-TET1 in BCPAP cells. (a) The expression of miRNAs and mRNAs was analyzed in NC and si-TET1 RNA groups in BCPAP cells. The fold change of miRNAs and mRNAs were set to be two times and 1.5 times, respectively, indicating obvious differences. The red ones are upregulated, and the green ones are downregulated. (b) Regulatory network map of classical oncogenes miR-7 and miR-15/16 and let-7. The statistically differentially expressed miRNAs are labeled in squares, and the statistically differentially expressed mRNAs are labeled in circles. The upregulated expression is shown in red, and the downregulated expression is shown in green.
miRNAs are an abundant class of 17- to 25-nucleotide, small, noncoding RNAs, identified as important regulators of many diverse biological processes. miRNAs could regulate the expression of protein-coding genes at the posttranscriptional level through binding to the 3′-untranslated region of target mRNAs [24]. Recent studies have focused on the regulating effect of miRNAs in tumorigenesis and progression by acting as oncogenes or tumor suppressors [25, 26]. In the present study, the miRNA array and mRNA expression array indicated that the expression of miR-7, miR-15/16 cluster (including miR-195, miR-15a, and miR-16), and let-7 family (let-7a, let-7d, let-7f, and let-7g) was significantly downregulated, while the expression of let-7e was upregulated after siRNA-TET1 treatment in BCPAP cells. A previous study reported that the expression of multiple oncogenes, including RAS, MYC, and HMG2 [30, 31]. The study indicated that the expression of let-7e, with the discrepant expression as other let-7 family members, was upregulated in BCPAP cells after siRNA-TET1. Similarly, a previous study reported that the expression level of let-7e increased in tissue and sera specimens of PTC [32].

In the coexpression network, the expression levels of WNT4 and FZD4 were found to be significantly increased as the target genes of dysregulated miRNAs after silencing TET1 in BCPAP cells. WNT4 is an extracellular ligand, and FZD4 is a cell membrane receptor of the Wnt pathway, which plays a key role in the activation of the Wnt signaling pathway [33]. The present study also found that the expression of proto-oncogenes CDK6, MCF2L, and EDN1 was upregulated along with WNT4 and FZD4. The expression of CDK6, as a proto-oncogene, was upregulated in numerous tumors [34, 35]. The overexpression of the MCF2L gene, encoding guanosine conversion factor, could activate the key regulatory factors of the Rho GTP family (Cdc42 and Rac1) and promote tumor metastasis in breast cancer cells [36]. The overexpression of EDN1 in zebrafish could promote cell proliferation, invasion, and metastasis and induce liver cancer [37]. The findings indicated that specific tumor-related miRNAs and the expression of their potential target genes were altered in TET1-depleted BCPAP cells. However, the relationship of TET1 with tumorigenesis deserves further exploration.

Taken together, the results suggested that the downregulated expression of TET1 might be correlated with the low expression of 5hmC and exerted a tumor-suppressive function in the BCPAP cell line. Specific miRNAs and mRNAs were dysregulated in BCPAP cells with the downregulated expression of TET1. These findings provided us new insights into the mechanism of thyroid cancer.

Data Availability

All data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

Shuang Yu and Yali Yin have contributed equally to this work.

Acknowledgments

The authors thank Professor Haixia Guan (The First Affiliated Hospital of China Medical University) for kindly giving them Nthy-ori3-1, BCPAP, and TPC-1 cell lines. This work was supported by grants from the National Natural Science Foundation of China (nos. 81702648 and 81772850) and National Key R&D Program of China (no. 2018YFC1314100).

Supplementary Materials

Supplementary Figure 1: the biological function of TET1 in TPC-1 cells. Supplementary Figure 2: coexpression network of miRNA chips and mRNA expression profiles after si-TET1 in BCPAP cells. Supplementary Table 1: association of miRNA chips and mRNA expression profiles after si-TET1 in BCPAP cells. Supplementary Table 2: gene expression profiling data between control and TET1-depleted BCPAP cells. Supplementary Table 3: gene expression profiling data between control and TET1-depleted BCPAP cells. (Supplementary Materials)

References

[1] W. Chen, R. Zheng, P. D. Baade et al., “Cancer statistics in China, 2015,” CA: A Cancer Journal for Clinicians, vol. 66, no. 2, pp. 115–132, 2016.
[2] R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2013,” CA: A Cancer Journal for Clinicians, vol. 63, no. 1, pp. 11–30, 2013.
[3] B. R. Haugen, E. K. Alexander, K. C. Bible et al., “2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer,” Thyroid, vol. 26, no. 1, pp. 1–133, 2016.
[4] Z. D. Smith and A. Meissner, “DNA methylation: roles in mammalian development,” Nature Reviews Genetics, vol. 14, no. 3, pp. 204–220, 2013.
[5] F. Neri, A. Krepelova, D. Incarnato et al., “Dnmt3L antagonizes DNA methylation at bivalent promoters and favors DNA methylation at gene bodies in ESCs,” Cell, vol. 155, no. 1, pp. 121–134, 2013.
[6] A. P. Feinberg and B. Vogelstein, “Hypomethylation distinguishes genes of some human cancers from their normal counterparts,” Nature, vol. 301, no. 5895, pp. 89–92, 1983.
[7] F. Gaudet, J. Graeme Hodgson, A. Eden et al., “Induction of tumors in mice by genomic hypomethylation,” Science, vol. 300, no. 5618, pp. 489–492, 2003.
[8] R. J. Klose and A. P. Bird, "Genomic DNA methylation: the mark and its mediators," *Trends in Biochemical Sciences*, vol. 31, no. 2, pp. 89–97, 2006.

[9] M. Tahiliani, K. P. Koh, Y. Shen et al., "Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1," *Science*, vol. 324, no. 5929, pp. 930–935, 2009.

[10] A. Maiti and A. C. Drohat, "Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine," *Journal of Biological Chemistry*, vol. 286, no. 41, pp. 35334–35338, 2011.

[11] C. Liu, L. Liu, X. Chen et al., "Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1," *PLoS One*, vol. 8, no. 5, Article ID e62828, 2013.

[12] F. Delhommeau, S. Dupont, V. D. Valle et al., "Mutation in TET2 in myeloid cancers," *New England Journal of Medicine*, vol. 360, no. 22, pp. 2289–2301, 2009.

[13] C. Du, N. Kurabe, Y. Matsushima et al., "Robust quantitative assessments of cytosine modifications and changes in the expressions of related enzymes in gastric cancer," *Gastric Cancer*, vol. 18, no. 3, pp. 516–525, 2015.

[14] C.-H. Hsu, K.-L. Peng, M.-L. Kang et al., "TET1 suppresses hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2," *Nature*, vol. 468, no. 7325, pp. 839–843, 2010.

[15] D. Globisch, M. Münzel, M. Müller et al., "Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates," *PLoS One*, vol. 5, no. 12, Article ID e15367, 2010.

[16] Q. Yang, K. Wu, M. Ji et al., "Decreased 5-hydroxymethylcytosine (5-hmC) is an independent poor prognostic factor in gastric cancer patients," *Journal of Biomedical Nanotechnology*, vol. 9, no. 9, pp. 1607–1616, 2013.

[17] Y. Zhang, K. Wu, Y. Shao et al., "Decreased 5-hydroxymethylcytosine (5-hmC) predicts poor prognosis in early-stage laryngeal squamous cell carcinoma," *American Journal of Cancer Research*, vol. 6, no. 6, pp. 1089–1098, 2016.

[18] H. Huang, X. Jiang, Z. Li et al., "TET1 plays an essential oncogenic role in MLL-rearranged leukemia," *Proceedings of the National Academy of Sciences*, vol. 110, no. 29, pp. 11994–11999, 2013.

[19] Y. Xu, F. Wu, L. Tan et al., "Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells," *Molecular Cell*, vol. 42, no. 4, pp. 451–464, 2011.

[20] C. R. Good, S. Panjarjan, A. D. Kelly et al., "TET1-Mediated hypomethylation activates oncogenic signaling in triple-negative breast cancer," *Cancer Research*, vol. 78, no. 15, pp. 4126–4137, 2018.

[21] H. Duan, Z. Yan, W. Chen et al., "TET1 inhibits EMT of ovarian cancer cells through activating Wnt/β-catenin signaling inhibitors DKK1 and SFRP2," *Gynecologic Oncology*, vol. 147, no. 2, pp. 408–417, 2017.

[22] M. Saiset, S. Floor, M. Tarabichi et al., "Thyroid cancer cell lines: an overview," *Frontiers in Endocrinology*, vol. 16, no. 3, p. 133, 2012.

[23] V. Ambros, "The functions of animal microRNAs," *Nature*, vol. 431, no. 7006, pp. 350–355, 2004.

[24] S. Volinia, G. A. Calin, C.-G. Liu et al., "A microRNA expression signature of human solid tumors defines cancer gene targets," *Proceedings of the National Academy of Sciences*, vol. 103, no. 7, pp. 2257–2261, 2006.